EW FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – EW

Core Points - Rosen Law Firm is reminding investors who purchased Edwards Lifesciences Corporation securities between February 6, 2024, and July 24, 2024, of the December 13, 2024, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must act by December 13, 2024, to serve as lead plaintiff [3] Company Details - The lawsuit alleges that during the class period, Edwards provided misleading information regarding its expected revenue for fiscal year 2024, particularly concerning the growth of its Transcatheter Aortic Valve Replacement (TAVR) product [5] - Defendants reportedly made strong commitments to the TAVR platform and claimed significant demand in lower-penetrated markets, which led to investor damages when the true information was revealed [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4] - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]